Want to see SE:PROGEN full AI Analyst Report?
Prostatype Genomics AB (PROGEN) Stock Statistics & Valuation Metrics
Total Valuation
Prostatype Genomics AB has a market cap or net worth of SEK 74.32M. The enterprise value is SEK 25.06M.
- Market Cap
- SEK 74.32M
- Enterprise Value
- SEK 25.06M
Share Statistics
Prostatype Genomics AB has 691,317,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 691,317,100
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Prostatype Genomics AB’s return on equity (ROE) is -1.68 and return on invested capital (ROIC) is -122.78%.
- Return on Equity (ROE)
- -1.68
- Return on Assets (ROA)
- -0.87
- Return on Invested Capital (ROIC)
- -122.78%
- Return on Capital Employed (ROCE)
- -1.47
- Revenue Per Employee
- 84.86K
- Profits Per Employee
- -6.36M
- Employee Count
- 7
- Asset Turnover
- 0.01
- Inventory Turnover
- 489.87
Valuation Ratios
The current PE Ratio of Prostatype Genomics AB is -0.20. Prostatype Genomics AB’s PEG ratio is -0.00.
- PE Ratio
- -0.20
- PS Ratio
- 3.50
- PB Ratio
- 0.97
- Price to FCF
- -0.17
- Price to Operating Cash Flow
- -0.30
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Prostatype Genomics AB had revenue of 594.00K and earned -44.50M in profits. Earnings per share was -1.32.
- Revenue
- 594.00K
- Gross Profit
- -37.62M
- Operating Income
- -39.08M
- Pretax Income
- -44.50M
- Net Income
- -44.50M
- EBITDA
- -36.89M
- Earnings Per Share (EPS)
- -1.32
Cash Flow
In the last 12 months, operating cash flow was -20.90M and capital expenditures -61,000, giving a free cash flow of -20.96M billion.
- Operating Cash Flow
- -20.90M
- Free Cash Flow
- -20.96M
- Free Cash Flow per Share
- -0.35
Dividends & Yields
Prostatype Genomics AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -590.78%
- Earnings Yield
- -595.69%
Stock Price Statistics
- Beta
- -0.24
- 52-Week Price Change
- -54.47%
- 50-Day Moving Average
- 0.13
- 200-Day Moving Average
- 0.25
- Relative Strength Index (RSI)
- 49.01
- Average Volume (3m)
- 8.43M
Important Dates
Prostatype Genomics AB upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Prostatype Genomics AB as a current ratio of 0.44, with Debt / Equity ratio of 19.98%
- Current Ratio
- 0.44
- Quick Ratio
- 0.43
- Debt to Market Cap
- 0.52
- Net Debt to EBITDA
- 0.10
- Interest Coverage Ratio
- -24.20
Taxes
In the past 12 months, Prostatype Genomics AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Prostatype Genomics AB EV to EBITDA ratio is -0.09, with an EV/FCF ratio of -0.15.
- EV to Sales
- 3.11
- EV to EBITDA
- -0.09
- EV to Free Cash Flow
- -0.15
- EV to Operating Cash Flow
- -0.15
Balance Sheet
Prostatype Genomics AB has SEK 392.00K in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 392.00K billion.
- Cash & Marketable Securities
- SEK 392.00K
- Total Debt
- SEK 0.00
- Net Cash
- SEK 392.00K
- Net Cash Per Share
- SEK 0.00
- Tangible Book Value Per Share
- -SEK 0.53
Margins
Gross margin is -2744.67%, with operating margin of -3694.18%, and net profit margin of -3737.97%.
- Gross Margin
- -2744.67%
- Operating Margin
- -3694.18%
- Pretax Margin
- -3737.97%
- Net Profit Margin
- -3737.97%
- EBITDA Margin
- -3369.03%
- EBIT Margin
- -3694.18%
Analyst Forecast
The average price target for Prostatype Genomics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 143.94%
- EPS Growth Forecast
- 70.95%
Scores
- Smart Score
- ―
- AI Score
- 42